Search Results

You are looking at 41 - 50 of 176 items for :

  • "cetuximab" x
  • All content x
Clear All
Full access

Al B. Benson III

previous trials), and the reality that much remains about the treatment of CRC that we do not understand. A series of clinical trials that included cetuximab or panitumumab retrospectively and prospectively evaluated the benefit of an anti-EGFR antibody

Full access

Wells A. Messersmith

treatment with the best chance of success. Adjuvant Therapy Although 11 agents have been approved by the FDA for CRC, only 3 are used in the adjuvant setting (fluorouracil [5-FU], capecitabine, and oxaliplatin) and only 2 (cetuximab and panitumumab

Full access

Harish N. Vasudevan and Sue S. Yom

cetuximab or immunotherapy, and consider the option of omitting concurrent chemotherapy altogether in low-risk patients. Finally, we summarize a biologic framework through which to study the mechanisms underlying interactions between RT and systemic therapy

Full access

Presenter: Robert I. Haddad

+ cetuximab. Patients with stable disease who received chemotherapy + cetuximab continued to receive cetuximab as maintenance until disease progression or unacceptable toxic effects. The study met its primary endpoint of OS, demonstrating an improvement of

Full access

Tanios Bekaii-Saab

% of colorectal tumors. Since initial approval of the EGFR-directed monoclonal antibodies cetuximab (2004) and panitumumab (2006) for clinical use in mCRC, strategies to improve selection of the appropriate patients have constantly been refined. In

Full access

Leonard Saltz

important agents in metastatic CRC. The European BOND trial confirmed previous studies in the United States and led to FDA approval of cetuximab. 6 The CRYSTAL trial, however, produced statistically significant but clinically disappointing results with

Full access

scientific peer-review process and are overseen by the ORP. Several NCCN-sponsored studies funded through the grant mechanism are highlighted below. Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) Plus Weekly Cetuximab Plus Radiation Therapy

Full access

Axel Grothey

control; this involves treatment until progression, maintenance therapy, and treatment beyond progression using these agents. Monoclonal antibodies directed against epidermal growth factor receptors (EGFRs), cetuximab and panitumumab, are interchangeable

Full access

Alan P. Venook

proved wrong was that a drug that works well in mCRC would also be effective in the adjuvant setting. In the NSABP and AVANT studies, 3 , 4 bevacizumab did not improve outcomes in patients with stage II or III disease, nor did cetuximab in the N0147

Full access

Mary E. Charlton, Amanda R. Kahl, Alissa A. Greenbaum, Jordan J. Karlitz, Chi Lin, Charles F. Lynch, and Vivien W. Chen

cured with surgery and neoadjuvant or adjuvant treatments, most are incurable, and treatment focuses on prolonging life and improving quality of life. Targeted agents such as epidermal growth factor receptor (EGFR) inhibitors, including cetuximab, can